Investors in the Biotech industry have had a rough few weeks. The benchmark SPDR S&P Biotech ETF (NYSEARCA:XBI)has fallen 26% since peaking in February of this year. However, Atossa Therapeutics (NASDAQ:ATOS) stock seems to have bucked the overall biotech bearish trend.

Source: luchschenF / Shutterstock.com

Despite the steep drop from all-time highs of $9, ATOS stock is still up for the year, trading around $3.50 today. That’s up about 270% since the beginning of this year and right with its 200-day moving average of $3.

The question is whether ATOS....More>>>

What happened

Having dropped from the lofty heights it reached only a few short months ago, Alector (NASDAQ:ALEC) stock was having another bad day on Wednesday. The biotech’s shares were down nearly 17% in mid-afternoon trading following some news from the C-suite.

So what

After market hours on Tuesday, Alector announced the departure of two high-level executives. It said that chief operating officer Shehnaaz Suliman and chief medical officer Robert Paul will step down following a “transition period,” and should continue to serve as advisors to the company....More>>>